Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.

[1]  D. E. Smith,et al.  Steady‐state pharmacokinetics of delavirdine in HIV‐positive patients: Effect on erythromycin breath test , 1997, Clinical pharmacology and therapeutics.

[2]  M. Borin,et al.  Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate , 1997, Clinical pharmacology and therapeutics.

[3]  Y. Lau,et al.  Determination of rifabutin in human plasma by high-performance liquid chromatography with ultraviolet detection. , 1996, Journal of chromatography. B, Biomedical applications.

[4]  M. G. Johnson,et al.  Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. , 1995, Journal of chromatography. B, Biomedical applications.

[5]  R. Wallace,,et al.  Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. , 1995, The Journal of infectious diseases.

[6]  R. N. Brogden,et al.  Rifabutin , 2012, Drugs.

[7]  K. Chong,et al.  Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro , 1994, Antimicrobial Agents and Chemotherapy.

[8]  R. Polk,et al.  Pharmacokinetic Drug Interactions with Antimicrobial Agents , 1993, Clinical pharmacokinetics.

[9]  L. Resnick,et al.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication , 1993, Antimicrobial Agents and Chemotherapy.

[10]  L. Resnick,et al.  Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Beaune,et al.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. , 1989, British journal of clinical pharmacology.

[12]  T. Merigan,et al.  Pharmacokinetics of rifabutin , 1989, Antimicrobial Agents and Chemotherapy.

[13]  D. Jabes,et al.  LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. , 1983, The Journal of antibiotics.

[14]  M. Strolin Benedetti,et al.  Autoinduction of rifabutin metabolism in man. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  M. Iseman,et al.  Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. , 1987, Drugs under experimental and clinical research.